新股认购：康寧傑瑞生物製藥（9966.HK）

Stock Code上市代號 9966.HK IPO Name股份名稱 Alphamab Oncology 康寧傑瑞生物製藥 Offer Price (HK$) 招股價(港元) 9.10 - 10.20 Lot Size (shares) 交易單位(股) 1,000 No. of Hong Kong Offer Share香港發售股數 17,942,000 No. of Global Offer Share全球發售股數 179,403,000 Sponsor保薦人 Morgan Stanley Asia Limited, CLSA Capital Markets Limited, Jefferies Hong Kong Limited Public Application Period招股日期 2 December 2019 (Mon) - 5 December 2019 (Thu) Application Deadline via Kim Eng經金英申請截止日期 4 December 2019 (Wed) 12:00 n.n. Fixed Date定價日期 5 December 2019 (Thu) Announcement Date公佈售股結果日期 11 December 2019 (Wed) Refund Date退款日期 11 December 2019 (Wed) Listing Date上市日期 12 December 2019 (Thu) Prospectus招股書 Alphamab Oncology HK$10.20 per Offer Share plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) 每股發售股份10.20港元，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費（須於申請時以港元繳足，多繳股款可根據最終定價予以退還） NUMBER OF PUBLIC OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS 可供申請認購的公開發售股份數目及應繳款項 No. of Public Offer Shares applied for Amount payable on application HK$ No. of Public Offer Shares applied for Amount payable on application HK$ No. of Public Offer Shares applied for Amount payable on application HK$ 申請認購的 公開發售股份數目 申請時應繳款項 港元 申請認購的 公開發售股份數目 申請時應繳款項 港元 申請認購的 公開發售股份數目 申請時應繳款項 港元 1,000 10,302.79 35,000 360,597.49 700,000 7,211,949.78 2,000 20,605.57 40,000 412,111.42 800,000 8,242,228.32 3,000 30,908.36 45,000 463,625.34 900,000 9,272,506.86 4,000 41,211.14 50,000 515,139.27 1,000,000 10,302,785.40 5,000 51,513.93 60,000 618,167.12 2,000,000 20,605,570.80 6,000 61,816.71 70,000 721,194.98 3,000,000 30,908,356.20 7,000 72,119.50 80,000 824,222.83 4,000,000 41,211,141.60 8,000 82,422.28 90,000 927,250.69 5,000,000 51,513,927.00 9,000 92,725.07 100,000 1,030,278.54 6,000,000 61,816,712.40 10,000 103,027.85 200,000 2,060,557.08 7,000,000 72,119,497.80 15,000 154,541.78 300,000 3,090,835.62 8,000,000 82,422,283.20 20,000 206,055.71 400,000 4,121,114.16 8,971,000 92,426,287.82 25,000 257,569.64 500,000 5,151,392.70 30,000 309,083.56 600,000 6,181,671.24 DISCLAIMERS: This document is prepared for internal/general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell, to subscribe for or purchase any securities or a solicitation of an offer to buy the securities referred to herein. Information provided in this document is strictly confidential. By accepting this document, you agree to be bound by the terms and limitations set out herein and to keep any information communicated or disclosed in this document in strict confidence. The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Kim Eng Securities (Hong Kong) Limited, its subsidiary and affiliates (collectively, “KESHK”) and consequently no representation is made as to the accuracy or completeness of this document by KESHK and it should not be relied upon as such. Accordingly, KESHK and its officers, directors, associates, connected parties and/or employe